Under 10% of individuals eligible to benefit from weight-loss injections including Wegovy are able to get them, states the World Health Organization as it releases its initial advice on the drugs.
Considering more than one billion individuals worldwide currently obese, it is advocating for broader and more equitable availability to GLP-1 medication.
Based on estimates, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.
"Our latest guidelines acknowledges that excess weight is a long-term condition that can be treated with holistic and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are significant obstacles to widespread availability to the treatments that can aid individuals in losing substantial body mass, says the agency.
Weight-Loss Drug Scarcity
Even under the present most optimistic scenario, the production of such drugs could only cover around 100 million people – fewer than 10% of the global need, as stated by the health organization.
The guideline urges nations and manufacturers to widen access, by strategies including patent sharing.
The intellectual property rights on the active ingredient – the main component of a leading brand – is scheduled to end in multiple nations in 2026.
How Weight-Loss Jabs Function
GLP-1 drugs mimick a biological compound to delay gastric emptying, suppress the appetite and increase feelings of fullness so users consume fewer calories.
Individuals usually start to lose weight within a few weeks of beginning the weekly injections.
Evidence points to people may put most of the weight back on within a year of halting the drug, as their normal appetite return.
Being above a healthy weight raises your risk for experiencing diseases, like diabetes, heart disease, stroke, and certain cancers.
Obesity affects individuals in all nations and was linked to over three and a half million deaths worldwide in 2024, according to the health agency.
